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Using the principles of public health genomics, we
examined the opportunities and challenges of
implementing personalized prevention pro-
grammes for cancer at the population level. Our
model-based estimates indicate that polygenic risk
stratification can potentially improve the effective-
ness and cost-effectiveness of screening pro-
grammes. However, compared with ‘one-size-fits-
all’ screening programmes, personalized screening
adds further layers of complexity to the organiza-
tion of screening services and raises ethical, legal
and social challenges. Before polygenic inheritance
is translated into population screening strategy,
evidence from empirical research and engagement
with and education of the public and the health
professionals are needed.
Keywords: ethical, legal and social issues, personal-
ized prevention, polygenic risk stratification, public
health genomics, screening.
Introduction
The success of the Collaborative Oncological Gene-
environment Study (COGS) [1] in identifying multi-
ple new genetic variants associated with the risk of
breast, prostate and ovarian cancers promises a
new era in personalized prevention. By stratifying
the population into several groups according to
genetic risk alone or combined with traditional
disease risk factors (such as age and family
history), standard public health interventions
could be applied differentially to each population
stratum with potentially more efficient outcome [2,
3]. However, the challenge remains how to trans-
late genomic knowledge into health improvement
programmes and disease prevention interventions
at the population level. Responding to such a
challenge represents the core work of public health
genomics.
Public health genomics is a relatively new disci-
pline that emerged in 1997 when small units were
established independently on both sides of the
Atlantic – the Office of Genetics and Disease
Prevention at the Centers for Disease Control and
Prevention in Atlanta, USA, and the Public Health
Genetics Unit in Cambridge, UK. Subsequently,
following a multidisciplinary expert meeting
supported by the Rockefeller Foundation at
Bellagio, Italy, in 2005, public health genomics
was formally defined as ‘the responsible and effec-
tive translation of genome-based knowledge and
technologies for the benefit of population health’,
and the broad content and methodology of this
discipline was specified [4, 5]. It was stated at the
Bellagio workshop that improving population
health would require an integrated and multidisci-
plinary approach, taking account of emerging
genome-based science and technologies and inte-
grating such knowledge with the humanities, social
sciences and population sciences, particularly
epidemiology. An important part of the definition
of public health genomics was that interventions
arising from genomic research should not be
introduced into clinical or public health practice
prematurely without the support of a solid evi-
dence base. The element of ‘responsibility’ in the
definition demonstrated the importance of the
societal context in which new technologies will be
applied and the collateral effects on individuals
and populations. Finally, the definition encom-
passed the view that implementation of new genetic
applications would require an active process,
involving multidisciplinary analysis, public dia-
logue and involvement, engagement with a wide
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range of stakeholders, informing public policy,
developing new programmes and services, strategic
planning and evaluating health services, and
training and educating health professionals, policy
makers and the public.
wIn this review, we illustrate the potential utility of
polygenic risk stratification in prevention pro-
grammes at a population level using the case of
population-based screening for breast and prostate
cancers [6]. Using the principles of public health
genomics,weexaminethechallengesofimplementing
personalizedscreeningprogrammes.Theseanalyses
were carried out as part of theWork Package 7 of the
COGS project funded by the Seventh Framework
ProgrammeoftheEuropeanCommission.
Polygenic risk stratification
The risk alleles identified by genome-wide associ-
ation studies individually confer a modest increase
in risk of disease (usually per-allele relative risk of
less than 1.5). Consequently, the predictive utility
of a genetic test based on a single risk allele is poor.
Even using a combination of multiple alleles, the
clinical utility of a polygenic test in predicting
future disease for the individual will be limited [7].
This is because most individuals are at only
slightly increased or decreased risk, and the dif-
ference is modest even for the small number at the
extremes of the distribution. However, discrimina-
tion (i.e. determining which individuals will or will
not experience disease) is not the only measure of
clinical utility of a risk prediction model. In disease
prevention, the aim is to stratify risk rather than to
discriminate events [8].
According to themultiplicativemodel, the polygenic
risk in the population at birth follows the normal
distribution when relative risk is plotted on a
logarithmic scale. The normal distribution is
defined by its mean and variance or spread [9].
The variance of the distribution of polygenic risk is
calculated from the risk allele frequencies and per-
allele relative risk [2, 10]. The distribution of relative
risk amongst cases is also log-normal with the same
variance as the population, but with a larger mean;
cases are on average at a higher prior risk of
developing cancer than the population [9]. Given
the variance andmean of the distribution of the log-
normal relative risk, the percentile rank associated
with a given polygenic relative risk (or age-condi-
tional absolute risk) threshold in the population or
in cases can be calculated [6].
Utility of polygenic risk stratification for personalized screening
We modelled the number of individuals eligible for
screening and the number of cases potentially
detectable by screening in a population undergoing
screening based on age alone, as compared to a
population undergoing personalized screening
based on the 10-year absolute risk of being diag-
nosed with breast or prostate cancer. We calculated
theconditional absolute risk taking intoaccountage
and polygenic risk profile. We set the risk threshold
equivalent to the threshold for eligibility in the age-
based screening programme [6].
In the case of breast cancer, we estimated the
polygenic risk based on 67 common genetic sus-
ceptibility variants [[11], which confer a polygenic
variance of 0.28 and explain approximately 14% of
the genetic component of breast cancer risk.
Compared with the UK National Health Service
Breast Screening Programme, which offers screen-
ing to women aged 47 to 73 years (10-year abso-
lute risk of being diagnosed with breast cancer of
2.5% or greater), personalized screening of women
aged 35 to 79 years at the same risk threshold
would result in 24% fewer women being eligible for
screening whilst potentially detecting 3% fewer
cases.
In the UK, there is no national screening pro-
gramme for prostate cancer, but a similar
approach could be applied if there were. We
estimated the polygenic risk of prostate cancer
based on 72 common susceptibility variants [12],
which confer a polygenic variance of 0.44 and
explain approximately 30% of the genetic compo-
nent of prostate cancer risk. Compared with a
hypothetical screening strategy based on age alone
in which men are eligible for screening from age 55
to 79 years (10-year absolute risk of being diag-
nosed with prostate cancer of 2% or greater),
personalized screening of men aged 45 to 79 years
at the same risk threshold would result in 19%
fewer men being eligible for screening at a cost of
4% fewer potentially screen-detectable cases.
The efficiency of personalized screening will
improve as more susceptibility variants are known.
Based on the currently known susceptibility vari-
ants for breast cancer, 43% of 35- to 79-year-old
women would be eligible for screening with 71% of
cases being potentially screen detectable. In a
hypothetical best-case-scenario analysis, assum-
ing all possible susceptibility variants for breast
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cancer were known (predicted polygenic variance of
1.44 [9, 13]), 28% would be eligible for screening
whilst potentially detecting 76% of cases. For
prostate cancer, based on the currently known
susceptibility variants, 51% of 45- to 79-year-old
men would be eligible for screening whilst poten-
tially detecting 92% of cases. In the best-case-
scenario (predicted polygenic variance of 1.58),
34% would be eligible whilst potentially detecting
89% of cases (Table 1).
Figure 1 shows how stratification based on the
absolute risk that is dependent on age and poly-
genic risk profile reclassifies individuals into differ-
ent risk groups, whereby some cancers that would
have been detected under age-based screening will
not be detected by personalized screening and vice
versa. Such reclassification may improve the ben-
efits and reduce some of the harms associated with
screening. A personalized screening programme
would enable the detection of cancer in younger
individuals who are at high risk. Prostate and
breast cancers detected in younger individuals tend
to behave more aggressively [14, 15]. So detecting
these cancers amongst younger individuals at high
risk may improve their prognosis. If polygenic low
risk is associated with indolent and possibly over-
diagnosed cancer, then not detecting cancer
amongst individuals at low risk may potentially
reduce the harms associated with overdiagnosis
and overtreatment.
Under an age-based screening strategy, all indi-
viduals within the age range will be eligible for
screening, whereas individuals will be invited for
screening at different ages based on their absolute
risk level under a personalized screening strategy.
For example, in the case of screening for prostate
cancer, instead of inviting all 55- to 79-year-old
men, 2%, 17% and 96% of men aged 47, 50 and
65 years, respectively, would be invited for screen-
ing. Thus, different individuals will undergo differ-
ent numbers of screening episodes during their
lifetime. A reduction in the number of individuals
offered screening may reduce the number of false-
positive screens, with a reduction in the harms
associated with false-positive results and the ben-
efit of saving further resources on diagnostic tests.
Table 1 The likely percentage of the population eligible for screening and of the cases potentially detectable by screening,
considering age-based and personalized screening for breast and prostate cancers with increasing numbers of known
susceptibility variants
Screening strategy
Population eligible for
screening (%)
Cases potentially detectable
by screening (%)
Age 35–79 years;
n = 13 126 890
Age 35–79 years;
n = 30 936
Breast cancer
Age-based screening (47–73 years) 57 72
Personalized screening (age 35–79 years and 10-year absolute risk ≥2.5%)
Currently known variants (variance = 0.28) 43 71
Variants explaining 50% of familial risk (variance = 0.72) 35 72
Variants explaining 100% of familial risk (variance = 1.44) 28 76
Age 45–79 years;
n = 8 655 126a
Age 45–79 years;
n = 22 836a
Prostate cancer
Age-based screening (55–79 years) 63 96
Personalized screening (age 45–79 years and 10-year absolute risk ≥2.0%)
Currently known variants (variance = 0.44) 51 92
Variants explaining 50% of familial risk (variance = 0.79) 45 91
Variants explaining 100% of familial risk (variance = 1.58) 34 89
aEstimates are based on the population and cancer registrations in 2002–2006 in England.
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However, to estimate the true benefits of person-
alized screening, we need to understand whether
and how tumour subtypes, screening test sensi-
tivity, the natural history of cancer and the prob-
ability of overdiagnosis vary by polygenic risk
profile. Further evidence from empirical data is
needed.
Challenges of implementing personalized screening
In addition to considering the utility of polygenic
risk stratification for personalized screening, there
are many other issues to consider before a risk-
tailored programme could be put into practice.
These are interdependent and include cost-effec-
tiveness, public and professional acceptability, and
organizational and a wide range of ethical, legal
and social issues.
Evaluation of cost-effectiveness
A screening programme becomes viable if it does
more good than harm at a reasonable cost [16]. A
personalized screening strategy involves the addi-
tional cost of polygenic risk profiling set against the
potential savings from repeat screening and diag-
nostic work-up of false-positive results. Our pre-
liminary cost–utility analysis comparing age-based
screening to a personalized screening programme
for prostate cancer indicates that personalized
screening would cost less and would increase the
number of quality-adjusted life years gained.
(a)
(b)
i. ii. iii.
i. ii. iii.
<47 years of age and 10-year absolute risk <2.5% ≥ 47 years of age and 10-year absolute risk <2.5%
<47 years of age and 10-year absolute risk ≥2.5% ≥ 47 years of age and 10-year absolute risk ≥2.5%
Fig. 1 Reclassification of women into different risk groups. a, Eligibility for screening: a population of 100 women, 35–
79 years of age, by age group and risk threshold (i), eligible for screening based on age alone (ii) or on age and polygenic risk
(iii). b, Potentially screen-detectable cases: a population of 100 women, 35–79 years of age, with breast cancer by age group
and risk threshold (i), detectable by screening based on age alone (ii) or on age and polygenic risk (iii).
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Exploring organizational and ethical, legal and social issues
We convened international multidisciplinary stake-
holder workshops, followed by ongoing detailed
research and policy analysis of the key issues
identified [17–19]. The workshop participants
included clinicians, geneticists, public health spe-
cialists, epidemiologists, ethicists, lawyers, social
scientists, screening programme managers, a jour-
nalist and public representatives. In addition to
panel discussions and small working groups, we
used hexagon modelling, a systematic technique
developed by IDON [20], to brainstorm, capture
and determine the priority of the issues raised. The
key issues are summarized below.
An overriding concern was whether eligibility for
screening based on a risk score that includes
genetic profiling alongside environmental and life-
style risk factors would be acceptable to the public,
health professionals and policy makers. Particu-
larly where there is already an established screen-
ing programme, such as that for breast cancer in
the UK, not or less frequently offering screening to
lower-risk groups may be perceived as service
rationing and unfair discrimination based on a
genetic profile that is unalterable and therefore not
under control of the individual. The DNA testing
involved in risk profiling may itself cause concerns
amongst the public about who might access these
data and whether they could be used for purposes
other than for health care or public health, such as
for medical research or forensic investigation, or to
inform decisions about insurance or employment.
The greatly increased complexity of a polygenic
risk-based screening programme could result in a
further set of issues. These are evident in both the
design and delivery of the programme. A major
organizational challenge will be to incorporate the
advances of the rapidly evolving field of genomics
and the changes in individuals’ environmental and
lifestyle risk factors, including their family history
of disease, into a dynamic risk estimation tool [21].
In terms of the environmental and lifestyle risk
factors, it is critical to determine how, when, with
what frequency and by whom this information will
be obtained and updated. For the genetic data, it
will be necessary to decide the age of sampling and
testing, details of the variants to be included,
whether rare highly penetrant mutations such as
BRCA1/2 will be included and whether to use a
bespoke set of variants related to the particular
condition or to use whole-genome sequencing for a
panel of common chronic diseases. In the latter
case, the relevant information regarding prevention
programmes could be extracted as and when
required [22].
The programme design also needs to set out the
different patterns of screening for which people in
differing risk strata will be eligible. Depending on
further research evidence, lower-risk groupsmaybe
offered screening less frequently and higher-risk
groupsmaybe offered screeningwithmore sensitive
(and possibly more expensive) tests, such as with
magnetic resonance imaging instead of mammog-
raphy for breast cancer screening [23]. To adapt
services already in place or to develop new ones,
substantial organizational effort will be required
supported by a range of evaluative research to
ensure that the level of extra value merits the
additional complexity and cost.
Finally, the delivery of the programme and, in
particular, the interaction of those at the frontline
of provision with participants must be considered
[24]. Individuals need to be able to make an
informed decision about whether to accept an offer
to participate. To support this and to protect the
public, it is important to establish policies, for
example, regarding: (i) the amount and type of
information to be provided to the public, (ii) how
the different levels of risk will be communicated,
(iii) the potential benefits and possible harms of
screening interventions for different risk strata and
(iv) regulations on data safeguarding. Health pro-
fessionals involved in service delivery will need
training to better understand how the risk scores
are determined and the evidence on which different
management options are based, to communicate
these effectively and to be able to provide support
to patients at various stages of the programme and
with different outcomes.
Conclusion
Polygenic risk stratification would potentially
improve the effectiveness and cost-effectiveness of
screening programmes. However, in terms of set-
up and delivery, a risk-tailored screening pro-
gramme is much more complex than a programme
with eligibility based on age alone. Any decision to
initiate a personalized screening programme
should first address the organizational and ethical,
legal and social issues and commit to public
engagement and education and to work with the
health professionals delivering the programme.
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From a wider perspective, the COGS project illus-
trates the enterprise of public health genomics. We
have shown how the practice of public health
genomics builds on a detailed understanding of
the underlying science and technology and incor-
porates elements of population sciences such as
epidemiology, health economics and consideration
of ethical, legal and social issues as well as policy
development and change management.
We have illustrated the complexity of knowledge
that must be integrated and the detailed planning,
consultation and development work that would be
required to underpin such a new programme. As
the definition of public health genomics suggests,
the ‘responsible translation of genomic technology
for the improvement of population health’, in its
widest sense, will demand no less.
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